TG Therapeutics, Inc. Public Market Comparables
Find the most relevant public market comparables for TG Therapeutics, Inc., including EV/Revenue and EV/EBITDA multiples to help you make informed investment decisions.
Company Overview
TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. They have received FDA approval for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis.
Business Model
Acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Target Customers
Adult patients with relapsing forms of multiple sclerosis (RMS), and potentially other patients with B-cell disorders in the future.
Specific Focus
Novel treatments for B-cell malignancies and autoimmune diseases, specifically relapsing forms of multiple sclerosis.
Location
New York, New York
CEO
Michael S. Weiss
Industry
Life sciences
Sub Sector
Biotechnology: Pharmaceutical Preparations
3yr Revenue Growth
153,625%
Website
Public Market Comparables
Below are the key valuation metrics for companies similar to TG Therapeutics, Inc. in the Healthcare sector. These metrics can help you understand how the market values companies with similar business models and growth profiles.
Looking for a comprehensive compset for TG Therapeutics, Inc.? Our platform provides detailed analysis of TG Therapeutics, Inc.'s competitive landscape, including financial metrics, growth trends, and market positioning. Get access to the full TG Therapeutics, Inc. compset by trying our platform today.
EV/Revenue Multiple
Min
0.0x
Median
0.0x
Max
00.0x
Unlock actual values by trying our platform
View Full DetailsEV/EBITDA Multiple
Min
00.0x
Median
00.0x
Max
00.0x
Unlock actual values by trying our platform
View Full Details
Unlock the Full TG Therapeutics, Inc. Compset
As a leading player in the Life sciences industry within the Healthcare sector, TG Therapeutics, Inc. operates in the specialized Biotechnology: Pharmaceutical Preparations sub-sector. Understanding how TG Therapeutics, Inc. compares to its public market comps is essential for accurate valuation and strategic decision-making.
Our comprehensive analysis includes detailed comparables (compsets) featuring similar companies in the Biotechnology: Pharmaceutical Preparations space, with complete financial metrics, growth trajectories, and competitive positioning insights that go beyond the surface-level data shown above.
Other Interesting Companies
Confluent, Inc.
Information Technology • Software & services
Confluent is a technology company that designs and develops data platforms helping organizations harness business value from stream data. They offer a cloud-native platform for managing real-time data streams, including Confluent Cloud and Confluent Platform, facilitating data streaming and integration. Their solutions cater to various industries, including financial services, retail, telecommunications, automotive, and technology.
MineSense Technologies Ltd.
Mining Technology • Hardware & semiconductors (including electronic devices)
MineSense Technologies Ltd. is a British Columbia-based technology company that enhances the sustainability of mining by improving the ore extraction and recovery process. They provide a platform for sensing and sorting low-grade ore with high precision, offering up to a 20% margin enhancement through reduced energy, water, and chemical needs. Their signature solution, ShovelSense, is a sensor installed on mining equipment that instantly characterizes ore mined with each bucket, improving efficiency, profitability, and sustainability.
Y-mAbs Therapeutics, Inc.
Biotechnology • Life sciences
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel, antibody-based therapeutic products for cancer treatment. They utilize technologies such as their investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Their product pipeline includes DANYELZA (naxitamab-gqgk), an FDA-approved treatment for relapsed or refractory neuroblastoma.
Get Your Custom Comparable Analysis
Need a more detailed analysis of TG Therapeutics, Inc. and its public market comparables? Our platform provides comprehensive valuation metrics, growth analysis, and more.
Try CompsetFinder Free